Press release content from Globe Newswire. The AP news staff was not involved in its creation.
PharmaTher Signs Exclusive Worldwide License Agreement for Patented Ketamine Formulation .
Newscope Capital CorporationJanuary 19, 2021 GMT
TORONTO, Jan. 19, 2021 (GLOBE NEWSWIRE) Newscope Capital Corporation (CSE: PHRM) (OTCQB: PHRRF), who through its wholly-owned subsidiary, PharmaTher Inc. (“PharmaTher”), is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals, is pleased to announce that PharmaTher has entered into an Exclusive Worldwide License Agreement (the “Agreement”) with the National Health Research Institutes (“NHRI”) for the development and commercialization of a patented combination formulation of FDA-approved ketamine and betaine (“KETABET™”) as a potential next-generation ketamine treatment for mental health, neurological and pain disorders.
NHRI Vice President Sytwu Huey-kang. CNA file photo
Taipei, Jan. 15 (CNA) The Central Epidemic Command Center (CECC) is planning to launch a public-private partnership to develop and produce antibody treatments against COVID-19, according to the National Health Research Institutes (NHRI).
Speaking to the media on Friday, NHRI Vice President Sytwu Huey-kang (司徒惠康) said the treatments, which will be used to treat COVID-19 patients and also provide short-term immunity for healthy individuals, are seen as a vital stopgap treatment until vaccines become widely available.
Sytwu said the NHRI, Academia Sinica, National Taiwan University Hospital and Chang Gung Medical Foundation each began working to develop COVID-19 antibody treatments last year, but their efforts have been largely uncoordinated.
Medigen to begin phase 2 vaccine candidate trials
By Kao Shih-ching / Staff reporter
Medigen Vaccine Biologics Corp (高端疫苗) on Wednesday said it plans to begin phase 2 clinical trials next week for its COVID-19 vaccine candidate and expects to apply by the end of June for emergency use authorization for the drug.
The company has started recruiting participants after last week obtaining Food and Drug Administration (FDA) permission to launch the phase 2 trials.
The company plans to recruit 3,700 participants, the most ever in such trials in Taiwan, as it aims to effectively examine the efficacy of its vaccine over the next three months, it said.
Researchers at Medigen Vaccine Biologics Corp. CNA photo Aug. 30, 2020
Taipei, Jan. 6 (CNA) Medigen Vaccine Biologics Corp. (MVC), a Taiwanese company whose COVID-19 vaccine candidate has been approved for second-stage clinical trials, said Wednesday that it will recruit 3,700 volunteers to participate in the trials over the next three months.
The company is partnering with 11 hospitals in Taiwan to speed up the process, with the hope of applying for emergency use authorization (EUA) for the vaccine in the second quarter of the year, said Lin Tzou-yien (林奏延), chairman of the National Health Research Institutes and chief convener of the trials.
The vaccine, called MVC-COV1901, was jointly developed by the United States National Institutes of Health (NIH) and Medigen, said Hsieh Szu-min (謝思民), the principal investigator of the trials.
Measures to halt betel nut chewing are showing results
By Lee I-chia / Staff reporter
The government has been successful in introducing public health measures to reduce the prevalence of betel nut chewing in men, especially among those in their 30s, researchers at the National Health Research Institutes (NHRI) and Health Promotion Administration (HPA) said yesterday.
Yang Yi-hsin (楊奕馨), an investigator at the National Institute of Cancer Research, said that more than 90 percent of oral cancer patients in Taiwan chew betel nuts, and oral cancer is the fourth leading cause of cancer deaths among men in the nation, with a standardized mortality rate of 15.04 per 100,000 population.